drugset / Trial / NCT07170150
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Timeline
- Start
- 2025-11-12
- Primary completion
- 2028-06-07
- Completion
- 2028-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trontinemab | Monoclonal antibody | — | Intravenous |